HOT NEWS
Pfizer and Medivation Announce Results From Two Phase 3 Studies in Dimebon » Pfizer Inc. (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) announced results from two Phase 3 trial...
Nycomed on track in 2009 with strong growth in Key Products » Nycomed was on track in 2009, with strong growth in Key Products and most emerging markets. Pantopra...
Bayer Successful in a Difficult Environment » 2009 was operationally one of the strongest years for the Bayer Group. "We were successful in a diff...
Phase III study of Avastin in advanced stomach cancer did not meet primary endpo... » Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the topline results from a global phase III trial inves...
Sanofi Pasteur's A(H1N1) Vaccine HUMENZA®* Recommended by European Medicines Ag... » Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announc...
FY2009: Merck KGaA Revenues Rise by 2.1% to € 7.7 Billion » Merck KGaA announced that Group total revenues rose 2.1% in 2009 - meeting the guidance given earlie...
GSK receives positive opinions in Europe for Tyverb® and Votrient™ » GlaxoSmithKline (GSK) announced that the European Medicines Agency's Committee for Medicinal Product...
My child matters Supports Seven New Childhood Cancer Care Projects » On the International Childhood Cancer Day, the International Union Against Cancer (UICC) and sanofi-...
Abbott Completes Acquisition of Solvay Pharmaceuticals » Abbott (NYSE: ABT) today announced that it has completed its EUR 4.5 billion ($6.2 billion) acquisit...
Merck Receives European Approval for ELONVA® (corifollitropin alfa injection) » Merck & Co., Inc., which operates outside the U.S. and Canada as MSD, today announced the European C...
Boehringer Ingelheim
Boehringer IngelheimThe Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and almost 38,900 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2007, Boehringer Ingelheim posted net sales of 10.9 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development. For more information please visit www.boehringer-ingelheim.com.

Boehringer Ingelheim RSS Channel
Filter     Display # 
# Article Title Hits
1 Boehringer Ingelheim and Priaxon announce a collaboration to research and develop novel treatments for cancer 525
2 Boehringer Ingelheim initiates first Phase III clinical trial in Ovarian Cancer 636
3 Milestone results in RE-COVER™ study - novel oral direct thrombin inhibitor dabigatran etexilate 799
4 Major European regulatory milestone in cardiovascular protection for Micardis® (telmisartan) 533
5 Boehringer Ingelheim and GlaxoSmithKline back EFA's call for urgent improvements in care for people with lung disease 441
6 Heinrich Wieland Prize 2009 awarded for outstanding achievements in the synthesis of key natural products 365
7 Boehringer Ingelheim Animal Health closes deal to acquire Animal Health Business from Pfizer 483
8 Boehringer Ingelheim receives approval from the European Commission for Mirapexin®/Sifrol 948
9 Access to HIV medication 454
10 Boehringer Ingelheim's diabetes pipeline continues to advance 1099
11 Boehringer Ingelheim Animal Health enters into agreement to acquire certain assets of Fort Dodge Animal Health from Pfizer 899
12 ERS COPD Research Award 2009 sponsored by Boehringer Ingelheim 802
13 Novel oral direct thrombin inhibitor dabigatran etexilate convincingly beats warfarin 2712
14 Good first six months in 2009 for Boehringer Ingelheim 601
15 European Commission approves statement on lipid improvement for Viramune® label 760
16 Boehringer Ingelheim and Vitae Pharmaceuticals announce a major collaboration 698
17 Outcome of new Mirapexin®/Sifrol® (pramipexole) study 968
18 European CHMP adopts negative opinion on Cymbalta for the treatment of fibromyalgia 831
19 Boehringer Ingelheim signs a license agreement with Evec Inc. for its fully-human antibody programme 580
 
Bookmark and Share

Banner